ALX Oncology Holdings Inc. (ALXO) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.9x

Market Cap

$277.94M

MomentumView details →

1D Return

−0.99%

YTD Return

+79.65%

RSI (14)

51.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.9x

Market Cap

$277.94M

RSI (14)

51.9

MomentumView details →

1D Return

−0.99%

YTD Return

+79.65%

SummaryUpdated Jun 1, 2026

ALX Oncology Holdings Inc. (NASDAQ:ALXO) is a clinical-stage immuno-oncology biotechnology company founded in 2015 and headquartered in South San Francisco, California. The company went public in July 2020 and focuses on developing innovative cancer therapies that harness the body's immune system to fight tumors. ALX Oncology is currently advancing multiple drug candidates through clinical trials, with its lead program targeting a cellular pathway that cancer cells use to evade immune detection.

Ask drillr about ALX Oncology Holdings Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−59.40%

ROA (TTM)

−50.30%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+48.64%

FCF YoY

+32.94%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+26.36%

EBITDA YoY

+30.79%

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

9.04%

Beats (12Q)

6/12

Next Q EPS Est

−$0.13

Avg Surprise (4Q)

−5.41%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

9.71x

Quick Ratio

9.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−80.89M

Op. CF (TTM)

−70.78M

Next earningsNov 6, 2026 →

Latest newsMore news →

ALX Oncology announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel.30d ago

ALX Oncology Holdings refinanced $10 million of existing debt and obtained an additional $20 million under a new $50 million loan facility, with $10 million uncommitted.30d ago

Similar companies

Entrada Therapeutics, Inc.TRDA CAMP4 Therapeutics CorporationCAMP MacroGenics, Inc.MGNX Cartesian Therapeutics, Inc.RNAC Alector, Inc.ALEC AC Immune S.A.ACIU Find similar companies →

Latest newsMore news →

ALX Oncology announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel.30d ago ALX Oncology Holdings refinanced $10 million of existing debt and obtained an additional $20 million under a new $50 million loan facility, with $10 million uncommitted.30d ago ALX Oncology Holdings reported a Q2 2026 net loss of $17.97 million, or $0.13 per diluted share, with cash and investments of $153.4 million as of June 30, 2026.30d ago